My Presentation

1,411 views

Published on

A presentation on Requirements for Registration of a New Drug by Nadim Dinani.


For Reference and file, contact nadimdinani@yahoo.co.in

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,411
On SlideShare
0
From Embeds
0
Number of Embeds
12
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • The FDA is divided into many centers; each center comprising a division with specific regulatory responsibilitiesThe main centers are as follows: CDER—Center for Drug Evaluation and Research CBER—Center for Biologics Evaluation Research CDRH—Center for Devices and Radiologic Health CFSAN—Center of Food Safety and Applied Nutrition CVM—Center for Veterinary Medicine NCTR—National Center for Toxicological Research
  • My Presentation

    1. 1. Requirements forRegistration of aNew Drug Presented by – Nadim Dinani MSc-I Bioanalytical Sciences Ramnarain Ruia College Seat no: - XYZABC
    2. 2. Overview
    3. 3. What is a New Drug ? New substance meant for medical use in humans except during local clinical trials has not been used & recognized in the country to any significant extent composition is not generally recognized, as safe and effective under the conditions recommended in its labeling by qualified experts
    4. 4.  fixed dose combination of 2 or more drugs , individually approved earlier for certain claims which are now proposed to be combined for the first time in fixed ratio marketed with modified or new claims but is already approved by the licensing authority for certain claims.
    5. 5. Why is Registration required ?Primary Goal Safety Quality EfficacySecondary Goal
    6. 6. Who provides registrationGuidelines? FDACDER CBER CDRH CFSAN CVM NCTR
    7. 7. Who is the regulatory agency in India?Central Drugs Standard Control Organization (CDSCO), and the office of its leader, the Drugs Controller General (India) [DCGI]
    8. 8. HOW is a New DrugRegistered ?
    9. 9. ApplicantApplication to Ethical IND application filing Committee to CDSCO Headquarters Report of ethical committee
    10. 10. IND application filing to CDSCO Headquarters Examination by New Drug Division Detailed Review by IND Committee Recommendation to DCGI IND Application ApprovedPositive response from Clinical Trials Ethical committee Starts
    11. 11. Completion of Clinical Trial Phase 3Application for New Drug Registration to CDSCO Reviewed by DCGI License is granted Refused to Grant License
    12. 12. Preclinical Studies Investigational New Drug Phase I Phase II Phase III New Drug Application FDA approval Phase IV
    13. 13. IND Investigational New Drug• synthesized and prepared for human administration?• identity and purity controlled?• protocol to be followed in proposed trial?• drug ?• qualifications (trial conductors and result evaluators)?• information sponsor provides clinicians?• convinced about safety of drug (enough to be tested on humans)?
    14. 14. Requirements for IND1. Cover Sheet (FDA Form-1571) [21 CFR 312.23(a)(1)]2. Table of Contents [21 CFR 312.23(a)(2)]3. Introductory Statement and General Investigational Plan [21 CFR 312.23(a)(3)]4. Investigators Brochure [21 CFR 312.23(a)(5)]5. Protocols [21 CFR 312.23(a)(6)]
    15. 15. 6. Chemistry, Manufacturing, and Control Information [21 CFR 312.23(a)(7)] a) Chemistry and Manufacturing Introduction b) Drug Substance [21 CFR 312.23 (a)(7)(iv)(a)] c) Drug Product [21 CFR 312.23 (a)(7)(iv)(b)] d) A brief general description of the composition, manufacture, and control of any placebo to be used in the proposed clinical trial(s) [21 CFR 312.23(a)(7)(iv)(c)] e) A copy of all labels and labeling to be provided to each investigator [21 CFR 312.23(a)(7)(iv)(d)] f) A claim for categorical exclusion from or submission of an environmental assessment [21 CFR 312.23(a)(7)(iv)(e)]
    16. 16. 7. Pharmacology and Toxicology Information [21 CFR 312.23(a)(8)] a) Pharmacology and Drug Distribution [21 CFR 312.23(a)(8)(i)] b) Toxicology: Integrated Summary [21 CFR 312.23(a)(8)(ii)(a)] i. A brief description of the design of the trials ii. A systematic presentation of the findings from the animal toxicology and toxico-kinetic studies. iii. Identification and qualifications of the individual(s) who evaluated the animal safety data and concluded iv. A statement of where the animal studies were conducted and where the records of the studies are available for inspection v. A declaration that each study subject to good laboratory practices (GLP) regulations was performed in full compliance
    17. 17. c) Toxicology - Full Data Tabulation [21 CFR312.23(a)(8)(ii)(b)] d) Toxicology - GLP Certification [21 CFR 312.23(a)(8)(iii)] e) Monitoring of Effects of these Clarifications8. Previous Human Experience with the Investigational Drug [21 CFR 312.23(a)(9)]9. 21 CFR 312.23(a)(10), (11) and (b), (c), (d), and (e)
    18. 18. Form FDA 1571
    19. 19. NDA New Drug Application• drug safe and effective?• Do benefits outweigh risks?• labeling (package insert) appropriate?• manufacturing and drug quality control methods adequate?
    20. 20. Requirements for NDA NDA Scientific DocumentationRequirements
    21. 21. Scientific Requirements Manufacturing Methodology Authentication Testing of Drug for - safety - Efficacy
    22. 22. Scientific Requirements Bioavailability and Bioequivalence Studies Data Container Closure Systems for Packaging Human Drugs and Biologics Microbiological analysis Data Clinical Research Data Statistical Data Human Pharmacokinetics and Bioavailability test Data Non-clinical pharmacology and toxicology studies Data Clinical evidence of effectiveness Summary of New Drug Samples and Analytical Data – for Method Validation Manufacture process of Drug Impurities in the Drug
    23. 23. Documentation for NDAFIRST: Documents• Organization & administrative information• Certificates, information & administrative documents about the product• Technical file documents• Clinical studies documentsSECOND: Attachments to the registration file• 15 copies of internal information• 15 copies of “The approved information form of the drug” duly completed• 2 samples of finished productTHIRD : separate copy of technical file for analysis purpose to Drug Control Laboratory
    24. 24. Form FDA 356h
    25. 25. Bibliography GUIDANCE FOR INDUSTRY ON PREPARATION OF COMMON TECHNICALDOCUMENT FOR IMPORT / MANUFACTURE AND MARKETING APPROVAL OF NEWDRUGS FOR HUMAN USE (NEW DRUG APPLICATION – NDA), CENTRAL DRUGS STANDARDCONTROL ORGANIZATION DIRECTORATE GENERAL OF HEALTH SERVICES MINISTRY OF HEALTH &FAMILY WELFARE GOVT. OF INDIA, NOVEMBER 2010 Richard A. Guarino ,M.D., New drug approval process, 5th edition, vol 190, 93-155 Dr. Harish Dureja, New Drug Approval Process: RegulatoryView, Pharmainfo.net online article – (link) http://www.fda.gov/RegulatoryInformation/Guidances/ucm129703.htm http://www.fda.gov/aboutfda/reportsmanualsforms/forms/default.htm http://cdsco.nic.in/ http://cdsco.nic.in/new_drugs_division.htm
    26. 26. THANK YOU FOR YOUR KIND ATTENTION

    ×